Anand B Karnad

  • 1179 Citations
  • 20 h-Index
1984 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Anand B Karnad is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 1 Similar Profiles
Neoplasms Medicine & Life Sciences
Breast Neoplasms Medicine & Life Sciences
Acquired Immunodeficiency Syndrome Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
House Calls Medicine & Life Sciences
Plasmacytoma Medicine & Life Sciences
Medical Oncology Medicine & Life Sciences
Multiple Myeloma Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 1991 2019


Hinck, A. P., Sarantopoulos, J., Curiel, T. J., Lafer, E. M., Weintraub, S. E., Karnad, A. B., Lechleiter, J. D., Thompson, I. M., Leach, R. J., Christy, B. A., Allred, C., Johnson, K., Padmanabhan, S., I-Tien, Y., Naylor, S., Gazitt, Y., Pollock, B. H., Mundy, G., Bonewald, L., Davis, S., Lee, E., Oishi, N., Hasty, E., Vijg, J. N. M. N., Herman, B. A., Johnson, K., Moyer, M., Windle, J., McGill, J., O'Connell, P., Clark, G., Kuhn, J., Wolf, R., Allred, D. C., Weiss, G., Boldt, D., Coltman, C. & Huang, H.

National Institutes of Health


Project: Research project

Hispanic Americans
Financial Management

Research Output 1984 2018

  • 1179 Citations
  • 20 h-Index
  • 72 Article
  • 2 Letter
  • 1 Review article
4 Citations (Scopus)

Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma

Kelly, K. R., Friedberg, J. W., Park, S. I., McDonagh, K., Hayslip, J., Persky, D., Ruan, J., Puvvada, S., Rosen, P., Iyer, S. P., Stefanovic, A., Bernstein, S. H., Weitman, S. D., Karnad, A. B., Monohan, G., VanderWalde, A., Mena, R., Schmelz, M., Spier, C., Groshen, S. & 5 others, Venkatakrishnan, K., Zhou, X., Sheldon-Waniga, E., Jane Leonard, E. & Mahadevan, D., Dec 15 2018, In : Clinical Cancer Research. 24, 24, p. 6150-6159 10 p.

Research output: Contribution to journalArticle

Aurora Kinase A
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Lymphoma, Large B-Cell, Diffuse
63 Citations (Scopus)

The biology and role of CD44 in cancer progression: Therapeutic implications

Chen, C., Zhao, S., Karnad, A. B. & Freeman, J. W., May 10 2018, In : Journal of Hematology and Oncology. 11, 1, 64.

Research output: Contribution to journalReview article

Epithelial-Mesenchymal Transition
Neoplastic Stem Cells
Hyaluronic Acid
20 Citations (Scopus)

Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): A randomised, phase 3 study

Herbst, R. S., Redman, M. W., Kim, E. S., Semrad, T. J., Bazhenova, L., Masters, G., Oettel, K., Guaglianone, P., Reynolds, C., Karnad, A. B., Arnold, S. M., Varella-Garcia, M., Moon, J., Mack, P. C., Blanke, C. D., Hirsch, F. R., Kelly, K. & Gandara, D. R., Jan 1 2017, (Accepted/In press) In : The Lancet Oncology.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Fluorescence In Situ Hybridization
Control Groups
2 Citations (Scopus)

Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?

Fountzilas, C., Stuart, S., Hernandez, B., Bowhay-Carnes, E., Michalek, J. E., Sarantopoulos, J., Karnad, A. B., Patel, S., Weitman, S. D. & Mahalingam, D., Jan 19 2017, (Accepted/In press) In : Investigational New Drugs. p. 1-6 6 p.

Research output: Contribution to journalArticle

Liver Diseases
Serum Albumin
Survival Analysis
14 Citations (Scopus)

Safety and pharmacodynamics of the PDE4 inhibitor roflumilast in advanced B-cell malignancies

Kelly, K., Mejia, A., Suhasini, A. N., Lin, A. P., Kuhn, J., Karnad, A. B., Weitman, S. D. & Aguiar, R. C., Mar 1 2017, In : Clinical Cancer Research. 23, 5, p. 1186-1192 7 p.

Research output: Contribution to journalArticle

Phosphodiesterase 4 Inhibitors
Phosphatidylinositol 3-Kinases